Imdelltra Shows Survival Benefit in Small Cell Lung Cancer

Imdelltra significantly improved progression-free and overall survival compared to chemotherapy in small cell lung cancer patients, with a median overall survival of 13.6 months versus 8.3 months. The ... Read More

Immunotherapy Advances Transform Small Cell Lung Cancer Care

Advances are reshaping treatment for small cell lung cancer, with immunotherapy and emerging options offering hope for longer survival and potential cures. Read More

VIDEO: 'Promising data' on small cell lung cancer presented at ASCO 2025

In this video, Lukas Delasos, DO, an associate staff member of the Lung Cancer Medical Oncology Program at the Cleveland Clinic Taussig Cancer Institute, provides updates in small cell lung cancer ... Read More

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether ... Read More

New Cancer Treatments That Improve Survival May Also Worsen Disparities

“he introduction of effective cancer innovations increased population-level health among patients with advanced lung cancer and melanoma but also widened the survival gap across county-level income ... Read More

Decline in SCLC Incidence Expected to Accelerate Through 2050

SCLC incidence in the US is projected to decline significantly through 2050, continuing a trend from 2000 to 2021. The study used SEER 17 data, showing a steady decline in SCLC cases across ... Read More

Ifinatamab deruxtecan demonstrates high response rate in previously treated extensive-stage small cell lung cancer

Patients diagnosed with recurrent or progressive extensive-stage small cell lung cancer (ES-SCLC) may benefit from treatment with ifinatamab deruxtecan (I-DXd), a B7-H3–directed antibody–drug ... Read More

Genentech’s Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer

– 46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options – – First Phase III ... Read More

Osimertinib plus chemotherapy improves progression-free survival in EGFR-mutated non-small cell lung cancer

A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on ... Read More

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ non-small cell lung cancer

Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with ... Read More